BBO-10203
As of the edition of 20 October 2026, BBO-10203 is a drug known only by a code name: in active development; acts on KRAS and PIK3CA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 3, 0 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 0 | 3 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bbot | Lead sponsor of trials | 2024 to now |